Inve India ▾

Gujarat Themis Biosyn share price & results

Gujarat Themis Biosyn Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Vapi, Gujarat-based fermentation manufacturer of Rifamycin pharma intermediates and APIs for anti-TB drugs

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue44.0 ₹ crore+22.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin48.0 %+9.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit11.0 ₹ crore+22.2% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity17.91 %−4.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-74.70 %−58.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)16.11 %+21.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 8 judged targets kept · 6 open · verdicts reflect calls analysed to Q1 FY27.

Gujarat Themis Biosyn Limited management guidance track record on Inve: 14 targets tracked across analysed earnings calls (3 achieved, 5 missed, 6 open).

TargetOriginal wordingSaidLatest callVerdict
Total CAPEX Plan₹200-plus crores over next 2-3 yearsQ2 FY22Q1 FY27:Confirmed ~₹370 crores invested over the last 3 years, largely completing the capex cycle. This exceeds the original ₹200cr target but is below the revised 'at least double' (₹400cr+) guidance, and was completed late.
Call transcript, Q1 FY27 · 10 Aug 2026		Achieved*
API Block CommissioningEnd of Q2 FY2024 (Sept 2023)Q2 FY23Q1 FY27:Acknowledged significant delay; API block has 'just begun now' due to fermentation capacity constraints, missing the Dec 2023 target by ~2.5 years.
Call transcript, Q1 FY27 · 10 Aug 2026		Missed
Revenue Growthhigh-teen basis
Call transcript, Q1 FY27 · 10 Aug 2026		Q1 FY27Q1 FY27:Guided for top-line growth on a 'high-teen basis' on a base case.
Call transcript, Q1 FY27 · 10 Aug 2026		New

Source: Inve Guidance Tracker for Gujarat Themis Biosyn Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Gujarat Themis Biosyn Limited's 14 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 11 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹352.6 +4.35% · +₹14.7

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −22.1% 1Y

₹250₹300₹350₹400₹450Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q1 FY27 — 10 Aug 2026

1Y: ₹452.45 on 24 Oct 2025 → ₹352.6. High ₹469.9 (27 Oct 2025), low ₹226.9 (30 Mar 2026).

Previous close
₹337.9
Market cap
₹4.4k Cr
52-week range
₹226.9 – ₹469.9
One year
−24.96%
Price to earnings (TTM to Jun 2026)
91.63×
Return on equity (TTM to Jun 2026)
17.91%

Overview

Symbol
NSE:GUJTHEM
Exchange
NSE
Currency
INR

What Gujarat Themis Biosyn Limited does

Based on the company's own presentations, annual report and earnings calls.

Gujarat Themis Biosyn Limited manufactures fermentation-based pharmaceutical intermediates (Rifamycin-S and Rifamycin-O) and Active Pharmaceutical Ingredients used in anti-tuberculosis and anti-infective drug formulations, selling in bulk to domestic and international pharmaceutical formulators, often through tender-driven orders. It operates from a single fermentation-and-synthesis-based plant in Vapi, Gujarat, and is forward-integrating into API manufacturing and new molecule R&D to serve regulated export markets such as the US and Europe. The company is part of the Themis group of companies (co-located with promoter Themis Medicare Limited) and has no subsidiaries, associates or joint ventures of its own. In April 2026 it signed an agreement to acquire Sanofi's global anti-TB and anti-infective branded generics portfolio, an asset-light deal intended to give it direct access to international markets, pending antitrust and FDI approvals.

Manufacturing facility
Single fermentation- and synthesis-based API/intermediates plant, Vapi (GIDC), Gujarat
Dedicated API block
New forward-integration API manufacturing block completed; validation batches underway
R&D facility
Phase 1 of new fermentation-led R&D facility commissioned
Target export markets
United States and Europe (regulated markets)
Corporate structure
No subsidiaries, associate or joint venture companies (standalone entity)
Group affiliation
Part of the Themis group; shares registered-office campus with promoter Themis Medicare Limited
Founded 1981Headquarters Vapi, Gujarat, India Company website

How the price took the results

close before → close after

Q1 FY27
+3.3%
10 Aug

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Gujarat Themis Biosyn Limited

Free account: one company. Everything above stays public.

Write why you follow Gujarat Themis Biosyn Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Gujarat Themis Biosyn Limited

Guides on how to read this kind of business and the numbers that matter.